Domů › Uroteliální (přechodnobuněčný) karcinom › Tennessee › Nashville
Klinické studie Uroteliální (přechodnobuněčný) karcinom v Nashville, TN
23 studií pro Uroteliální (přechodnobuněčný) karcinom hledá účastníky v lokalitách v Nashville a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Probíhá náborFáze 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Probíhá náborFáze 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Probíhá náborFáze 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Probíhá náborFáze 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
Probíhá náborFáze 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Probíhá náborObservační studie
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Probíhá náborFáze 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- a dalších 9
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Probíhá náborFáze 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Probíhá náborFáze 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Probíhá náborFáze 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Probíhá náborFáze 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Probíhá náborFáze 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Probíhá náborFáze 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Probíhá náborFáze 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Probíhá náborFáze 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Probíhá náborFáze 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Probíhá náborFáze 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Probíhá náborFáze 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Probíhá nábor
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Probíhá náborFáze 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Nashville
Studie Uroteliální (přechodnobuněčný) karcinom v jiných městech
- New York City, NY22 studií
- Houston, TX19 studií
- Dallas, TX18 studií
- Edison, NJ18 studií
- Los Angeles, CA17 studií
- Queens, NY15 studií
- Chicago, IL14 studií
- Arlington, VA12 studií
- Boston, MA11 studií
- San Antonio, TX11 studií
- Austin, TX10 studií
- Orange, CA10 studií
Další studie v Nashville
- Nemalobuněčný plicní karcinom97 studií
- Rakovina prsu81 studií
- Metastatický karcinom70 studií
- Kolorektální karcinom69 studií
- Rakovina (všechny typy)65 studií
- Rakovina vaječníků49 studií
- Rakovina prostaty43 studií
- Rakovina plic40 studií
- Squamózní buněčný karcinom hlavy a krku39 studií
- Rakovina slinivky břišní39 studií
- Rakovina endometria38 studií
- Melanom33 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.